An effective second-generation outer surface protein A-derived Lyme vaccine that eliminates a potentially autoreactive T cell epitope.
暂无分享,去创建一个
B. Huber | E. Brown | Theresa A Willett | Abbie L Meyer | Eric L Brown | Brigitte T Huber | A. Meyer | T. A. Willett
[1] J. Ohnishi,et al. Antigenic and genetic heterogeneity of Borrelia burgdorferi populations transmitted by ticks. , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[2] A. Steere,et al. The clinical evolution of Lyme arthritis. , 1987, Annals of internal medicine.
[3] U. Schaible,et al. Experimental Borrelia burgdorferi infection in inbred mouse strains: Antibody response and association of H‐2 genes with resistance and susceptibility to development of arthritis , 1991, European journal of immunology.
[4] M. Kramer,et al. Plasmid DNA and protein vaccination of mice to the outer surface protein A of Borrelia burgdorferi leads to induction of T helper cells with specificity for a major epitope and augmentation of protective IgG antibodies in vivo , 1996, European journal of immunology.
[5] B. P. Guo,et al. Resistance to Lyme disease in decorin-deficient mice. , 2001, The Journal of clinical investigation.
[6] D. Parenti,et al. Immunogenicity of a recombinant Borrelia burgdorferi outer surface protein A vaccine against Lyme disease in children. , 1999, The Journal of pediatrics.
[7] A. Steere,et al. Chronic Lyme arthritis. Clinical and immunogenetic differentiation from rheumatoid arthritis. , 1979, Annals of internal medicine.
[8] A. Steere,et al. Molecular Mimicry in Lyme Arthritis Demonstrated at the Single Cell Level: LFA-1αL Is a Partial Agonist for Outer Surface Protein A-Reactive T Cells1 , 2001, The Journal of Immunology.
[9] E. Fikrig,et al. Borrelia burgdorferi P35 and P37 proteins, expressed in vivo, elicit protective immunity. , 1997, Immunity.
[10] A. Steere,et al. Autoimmune mechanisms in antibiotic treatment-resistant lyme arthritis. , 2001, Journal of autoimmunity.
[11] J. Piffaretti,et al. Association between different clinical manifestations of Lyme disease and different species of Borrelia burgdorferi sensu lato. , 1995, Research in microbiology.
[12] J. Weis,et al. Rapid and Sensitive Quantification ofBorrelia burgdorferi-Infected Mouse Tissues by Continuous Fluorescent Monitoring of PCR , 1999, Journal of Clinical Microbiology.
[13] C. Schmid,et al. Vaccination against Lyme disease with recombinant Borrelia burgdorferi outer-surface lipoprotein A with adjuvant. Lyme Disease Vaccine Study Group. , 1998, The New England journal of medicine.
[14] F. Falcioni,et al. HLA-DR4-IE chimeric class II transgenic, murine class II-deficient mice are susceptible to experimental allergic encephalomyelitis , 1996, The Journal of experimental medicine.
[15] S. Malawista,et al. A vaccine consisting of recombinant Borrelia burgdorferi outer-surface protein A to prevent Lyme disease. Recombinant Outer-Surface Protein A Lyme Disease Vaccine Study Consortium. , 1998, The New England journal of medicine.
[16] E. Fikrig,et al. Molecular Adaptation of Borrelia burgdorferi in the Murine Host , 2002, The Journal of experimental medicine.
[17] V. Sikand,et al. Safety and immunogenicity of a recombinant Borrelia burgdorferi outer surface protein A vaccine against lyme disease in healthy children and adolescents: a randomized controlled trial. , 2001, Pediatrics.
[18] A. Steere,et al. The clinical spectrum and treatment of Lyme disease. , 1984, The Yale journal of biology and medicine.
[19] M. Hanson,et al. Evidence for Vaccine Synergy between Borrelia burgdorferi Decorin Binding Protein A and Outer Surface Protein A in the Mouse Model of Lyme Borreliosis , 2000, Infection and Immunity.
[20] Robert T. Chen,et al. Adverse event reports following vaccination for Lyme disease: December 1998-July 2000. , 2002, Vaccine.
[21] B. P. Guo,et al. Active and Passive Immunity against Borrelia burgdorferi Decorin Binding Protein A (DbpA) Protects against Infection , 1998, Infection and Immunity.
[22] Y. Lobet,et al. Evaluation of the safety, reactogenicity and immunogenicity of three recombinant outer surface protein (OspA) lyme vaccines in healthy adults. , 1996, Vaccine.
[23] A. Steere,et al. Early and late antibody responses to full-length and truncated constructs of outer surface protein A of Borrelia burgdorferi in Lyme disease , 1995, Infection and immunity.
[24] A. Steere,et al. Binding of outer surface protein A and human lymphocyte function-associated antigen 1 peptides to HLA-DR molecules associated with antibiotic treatment-resistant Lyme arthritis. , 2003, Arthritis and rheumatism.
[25] Y. Lobet,et al. Reactivity with a specific epitope of outer surface protein A predicts protection from infection with the Lyme disease spirochete, Borrelia burgdorferi , 1997, Infection and immunity.
[26] G. Maupin,et al. Assessing the prevention effectiveness of local Lyme disease control. , 1999, Journal of public health management and practice : JPHMP.
[27] W. N. Kelley,et al. Textbook of Internal Medicine , 1989 .
[28] D F Stroup,et al. Occupational Risk of Lyme Disease in Endemic Areas of New York State , 1988, Annals of the New York Academy of Sciences.
[29] A. Steere,et al. ASSOCIATION OF CHRONIC LYME ARTHRITIS WITH HLA‐DR4 and HLA‐DR2 ALLELES , 1990, The New England journal of medicine.
[30] A. Steere,et al. Direct enumeration of Borrelia-reactive CD4 T cells ex vivo by using MHC class II tetramers. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[31] W. Todd,et al. Lyme disease spirochetes and ixodid tick spirochetes share a common surface antigenic determinant defined by a monoclonal antibody , 1983, Infection and immunity.
[32] J. Dunn,et al. Outer surface protein A (OspA) from the Lyme disease spirochete, Borrelia burgdorferi: high level expression and purification of a soluble recombinant form of OspA. , 1990, Protein expression and purification.
[33] T Hoshi,et al. Biophysical and molecular mechanisms of Shaker potassium channel inactivation , 1990, Science.
[34] C. Rosé,et al. Arthritis following recombinant outer surface protein A vaccination for Lyme disease. , 2001, The Journal of rheumatology.
[35] A. Steere,et al. T helper 1 response is dominant and localized to the synovial fluid in patients with Lyme arthritis. , 1998, Journal of immunology.
[36] E. Fikrig,et al. Inability of truncated recombinant Osp A proteins to elicit protective immunity to Borrelia burgdorferi in mice. , 1993, Journal of immunology.
[37] A. Steere,et al. Identification of LFA-1 as a candidate autoantigen in treatment-resistant Lyme arthritis. , 1998, Science.
[38] A. Steere,et al. Association of treatment-resistant chronic Lyme arthritis with HLA-DR4 and antibody reactivity to OspA and OspB of Borrelia burgdorferi , 1993, Infection and immunity.
[39] E. Fikrig,et al. Borrelia burgdorferi Gene Expression In Vivo and Spirochete Pathogenicity , 2000, Infection and Immunity.
[40] Z. Nagy,et al. Precise prediction of major histocompatibility complex class II-peptide interaction based on peptide side chain scanning , 1994, The Journal of experimental medicine.
[41] E. Fikrig,et al. A monoclonal antibody to OspA inhibits association of Borrelia burgdorferi with human endothelial cells , 1993 .
[42] A. Frey,et al. Protection against tick-transmitted Lyme disease in dogs vaccinated with a multiantigenic vaccine. , 2001, Vaccine.
[43] C H Schmid,et al. Two controlled trials of antibiotic treatment in patients with persistent symptoms and a history of Lyme disease. , 2001, The New England journal of medicine.
[44] E. Fikrig,et al. Elimination of Borrelia burgdorferi from vector ticks feeding on OspA-immunized mice. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[45] M. Kramer,et al. Therapeutic passive vaccination against chronic Lyme disease in mice. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[46] H. Müller-Hermelink,et al. Recombinant outer surface protein a from Borrelia burgdorferi induces antibodies protective against spirochetal infection in mice. , 1991, The Journal of infectious diseases.
[47] A. Steere,et al. The spirochetal etiology of Lyme disease. , 1983, The New England journal of medicine.
[48] Haiyang Li,et al. Crystal structure of Lyme disease antigen outer surface protein A complexed with an Fab. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[49] A. Barbour,et al. Experimental immunization against Lyme borreliosis with recombinant Osp proteins: An overview , 1996, Infection.
[50] B. Luft,et al. Human T lymphocyte response to Borrelia burgdorferi infection: no correlation between human leukocyte function antigen type 1 peptide response and clinical status. , 2003, The Journal of infectious diseases.
[51] Maria Labandeira-Rey,et al. VraA (BBI16) Protein of Borrelia burgdorferi Is a Surface-Exposed Antigen with a Repetitive Motif That Confers Partial Protection against Experimental Lyme Borreliosis , 2001, Infection and Immunity.
[52] E. Fikrig,et al. Borrelia burgdorferi OspA is an arthropod-specific transmission- blocking Lyme disease vaccine , 1996, The Journal of experimental medicine.